StockIQ.techAmgen Inc. (AMGN) Stock Analysis
Free AI-powered analysis and research for Amgen Inc. stock
Sector: Healthcare
AMGN snapshot
Data as of 3 Nov 2026 close. Updated daily.
Amgen Inc. scores 83/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 93% of its 52-week range, up 56.2% over the past year. Latest reported figures show a profit margin of 23.0%, return on equity of 91.5% and revenue growth of +9.5%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Excellent Profit Margin (23.0%): +10
- High Debt (4.90 D/E): -10
- Weak Liquidity (1.37 Current Ratio): -5
- Excellent ROE (91.5%): +8
- High P/B (21.32): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+56.2% over 1 year): +10
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full AMGN report
Amgen Inc. (AMGN) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze AMGN Now →📰 Latest Update
RNA Targeting Small Molecule Drug Discovery Market - Global Strategic Business Report: Secure a US$5.3B Market by 2030 as Amgen, AstraZeneca, Roche and Merck Accelerate RNA Pipelines
Mon, November 2, 2026 at 3:50 PM UTC 4 min read
The global RNA targeting small molecule drug discovery market, valued at US$1.8 billion in 2024, is projected to reach US$5.3 billion by 2030, growing at a CAGR of 19.9%. Companies like Amgen, AstraZeneca, Roche, and Merck are advancing their RNA-focused pipelines, leveraging AI-driven screening and partnerships to enhance drug discovery in oncology and rare diseases. The report highlights the increasing importance of RNA as a therapeutic target and the rise of specialized biotechnology startups in this sector.